The United States Food and Drug Administration (FDA) has approved multiple PARP inhibitors for the treatment of BRCA mutation-positive breast cancer (Mccann and Hurvitz, 2018) and advanced ovarian cancer (Colombo et al., 2018). The gene discussed is PARP1; the disease is ovarian carcinoma.